HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

Cuts to U.S. foreign aid will endanger HIV treatment and prevention services globally and are likely to reverse decades of ...

During his 36-year career at Cancer Center, Michael Emerman, PhD, made fundamental discoveries about HIV, the retrovirus that ...

On June 26, 2025, Gilead Sciences, Inc. (NASDAQ:GILD) announced the development of its ongoing Phase 2/3 clinical trial that is expected to treat HIV in pediatric patients.

The final, formatted version of the article will be published soon. Background: Moyamoya disease (MMD) is an idiopathic chronic intracranial vascular stenosis and occlusion disease However, there is ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show striking effectiveness across diverse populations at high risk for HIV.

The Multiplo® TP/HIV rapid self-test provides immediate results from a simple finger-prick blood sample. A positive result can then be confirmed through lab testing, enabling people to quickly ...